Introduction
Biobankonomics is the economic theory behind the creation, functioning, and effects of biobanks. It is more important comparing the value created by biobanks to the resources consumed than simply looking at money earned or spent. Precision medicine, research, and healthcare innovation are all fueled by biobanks, which are not like other businesses because they hardly ever “profit” in the traditional sense. Biobanknomics examines the economics of biobanking with a focus on Cost analysis, financial sustainability, Value creation, Economic impact on science, innovation, and public health, as well as answering questions such as: How much does it cost to establish and operate a biobank? What are the financial and societal returns on this investment? How can biobanks be managed and funded sustainably? and cutting down on unnecessary expenses. The intent of the article is to dissect the economic aspects, efficiency indicators of biobanking and the sustainability of biobanks.
Components of Biobankonomics
(A) Cost Analysis
- Capital Expenditure: Establishing a biobank is similar to creating an advanced biological library. Rent/buildings, Robotic sample handling systems, liquid nitrogen tanks, ultra-low temperature freezers (-80°C), and secure IT infrastructure for data can all cost millions of dollars up front.
- Operational Expenditure: Operating expenses are constant and include compensation for qualified personnel (biologists, bioinformaticians), energy bills for cold storage, and adherence to laws such as GDPR and HIPAA. Just keeping the lights (and freezers) on, could cost a mid-sized biobank $1–5 million a year.
- Costs of Sample Acquisition: Sample collection is not free. It entails collaborations with clinics, procedures for ethical consent, and occasionally paying donors (either directly or indirectly through research grants). Due to scarcity, obtaining a single sample for rare diseases can be disproportionately costly.
(B) Models of Revenue Funding
- Public Funding: Many biobanks, such as the UK Biobank, are financed by taxpayer funds or government grants, which are frequently supported by claims of benefits to public health. The UK government and Wellcome Trust, for example, initially contributed roughly £62 million to the UK Biobank.
- Private/Commercial Models: Certain biobanks impose access fees on pharmaceutical companies, biotech companies, and researchers. $200 to $2,000 may be charged for each sample, depending on the quality, rarity, and related data.
- Hybrid Models: Public-private partnerships are increasingly used to finance biobanks; during these partnerships, governments cover the initial costs, but industry access agreements generate revenue.
- Philanthropy & Donations: Patient advocacy organizations or nonprofit foundations fund some biobanks, especially those for rare diseases and disease-specific biobanks (e.g., cancer or uncommon genetic illnesses).
(C) Value Creation (Economic Output)
Biobanks rarely generate direct profits; instead, their “output” is frequently indirect. They make personalized medicine, drug discovery, and diagnostic tools possible. A single biobank sample could help create a drug worth billions of dollars, but the biobank might only receive a small portion of the money in the form of fees.
Biobanks make research more efficient as well. In the absence of biobanks, each researcher would have to find volunteers and gather samples on their own, which would be a greatly redundant process. Biobanks could be considered as biology’s “cloud storage,” which eliminates unnecessary expenses. Better health outcomes translate into economic gains through lower healthcare costs or higher productivity, which are harder to measure but have a substantial impact over decades. Sources of revenue include:
- Access/Usage fees: Charging researchers (public/private sector) to access samples or data.
- Partnerships & Grants: Collaborations with academia, pharmaceutical companies, or government agencies.
- Service contracts: Sample processing, storage, or analysis services.
(D) Market Forces and Demands
- Supply and demand: The willingness of donors, ethical standards, and the prevalence of diseases all affect the “supply” of samples. “Demand” is generated by industry and researchers, fueled by developments in precision medicine and genomics.
- Regulation: Stringent laws pertaining to consent and privacy (e.g., European Union GDPR), which raises operating costs but is required to preserve public confidence. Noncompliance can quickly destroy a biobank’s funding and reputation.
- Long-Term Sustainability: After receiving their first grants, many biobanks cannot sustain it. Samples may remain unutilized for years, incurring storage costs, with no assurance of future profits or scientific benefits. Biobanks can be sustainably funded and managed effectively by cutting down on unnecessary expenses.
Efficiency Indicators in Biobanking
Economic efficiency indicators are based on impact and resource optimization because biobanks are not normally profit-driven organizations. Here are key indicators, often used by stakeholders to assess performance:
- Cost per Sample Stored: This is calculated by dividing total operational costs by the number of samples. This varies widely—small, specialized biobanks might have higher costs per sample due to niche focus, while large ones benefit from economies of scale. For example, large biobanks like UK Biobank achieve economies of scale, with costs as low as $10-20 per sample/year, while smaller ones might hit $100+ due to lower volume. A rough benchmark for large biobanks might be $10-$50 per sample per year, though this depends heavily on infrastructure and location.
- Sample Utilization Rate: This is the percentage of samples accessed for research annually. A low rate signals inefficiency—either poor marketing to researchers or irrelevant inventory. High utilization suggests the biobank is meeting demand efficiently.
- Research Output per Dollar: This is the number of publications, patents, or clinical trials enabled per unit of funding. For example, the UK Biobank has supported over 2,000 studies since 2012—a strong return on investment.
- Data Quality and Access Speed: Economic value hinges on usable samples tied to robust, anonymized datasets. Time taken to fulfill researcher requests is also a key metric—delays mean lost opportunity costs.
- Sample Quality Metrics: Efficiency isn’t just about numbers; it’s about usability. Indicators like sample integrity (e.g., percentage of DNA/RNA degradation after storage) or compliance with standardized protocols (like ISO 20387 for biobanking) show how well resources are used to maintain valuable material.
- Time to Access: How quickly can a researcher request and receive a sample or data? Streamlined processes (digital catalogs, automated retrieval) improve efficiency, while bureaucratic delays or poor IT systems drag it down.
- Data Linkage Efficiency: Many biobanks store not just samples but associated clinical or genomic data. The ability to link samples to high-quality, anonymized datasets (and make them searchable) is a critical efficiency marker. Poor data management means wasted potential.
- Return on Investment (ROI) for Research: Harder to quantify, but stakeholders often look at the number of publications, patents, or clinical trials enabled by a biobank’s resources. For example, the UK Biobank, with over 500,000 participants’ data, has contributed to thousands of studies—a strong indicator of a great success.
Challenges in Biobanknomics
Challenges in biobanknomics include assigning value to public good created by biobanks, balancing open science vs. commercial interests, modeling indirect economic impacts (e.g., earlier disease detection) and sustaining operations beyond initial funding cycles.
How can biobanks be sustained economically?
Sustainability is the ability of a biobank to remain functional, effective, and competitive over its expected lifetime. Being sustainable involves balancing a biobank’s financial, social, and operational dimensions, with the overall aim to create value. In order to sustain biobanks economically, a multifaceted approach that balances financial viability with ethical and social responsibility must be adopted. This approach involves:
- Diversification of Revenue Streams: This can be achieved via public-private partnerships by collaboration with pharmaceutical companies and research institutions for sample access, data sharing, or service contracts. Analytical services such as genomic sequencing and data analysis can be offered to academic and commercial clients by leveraging the biobank’s expertise and infrastructure. Funds can also be raised for the biobank’s sustainability by organizing conferences, workshops, or training programs. Offering courses or certifications in biobanking management is also a means of creating revenue streams and building a skilled workforce.
- Cost Management and Efficiency: This involves cutting down on operational costs by investing in automation, AI, and cloud-based solutions. Cost-effective cryopreservation or digitization of metadata should be implemented to lower long-term storage expenses.
- Collaborative Models: This can be achieved via shared networks, which involves the establishment of regional or global biobank networks to pool resources, share data, and distribute costs, particularly for rare diseases. Universities, hospitals, and NGOs can also collaborate to minimize individual financial burdens.
- Funding Mechanisms: Funding can be secured through grants from healthcare initiatives, NGOs, and international bodies whose missions align with that of the biobank. Support from the government can be sought through advocating for sustained public investment, as seen in initiatives like UK Biobank, while exploring self-sufficiency pathways.
- Value Creation: This can be achieved by highlighting biobank contributions to medical breakthroughs, thereby attracting long-term investment and collaboration. Value-added services, such as personalized health insights or insurance products, can be developed using biobank data.
- Stakeholders: The interaction and relationship with stakeholders is crucial for sustainable biobanking. There are different stakeholders involved in running the biobank, collecting and using the samples and data, and providing support, funds, and revenues. Stakeholders include the hosting institution, healthcare staff, users (researchers, biotech and pharmaceutical companies, policymakers, and healthcare professionals). The key to success for any commercial or non-profit organisation is the satisfaction of its key stakeholders (Bourne 2009, Bryson 2011, Bjugn, Casati 2012). The same is applicable to biobanks. Biobanks do not exist in isolation, but within an extensive ecosystem of stakeholders.
Conclusion
Biobanks must adopt hybrid models combining public support, private engagement, and community-driven initiatives in their Biobanknomics. Prioritizing ethical practices and technological innovation ensures they remain financially resilient while fulfilling their mission to advance healthcare. Each biobank’s strategy should be fashioned to its structure and goals, emphasizing adaptability and stakeholder inclusivity.
References
- Albert Monique, John Bartlett, Randal N. Johnston, Brent Schacter, and Peter Watson. 2014. Biobank bootstrapping: Is biobank sustainability possible through cost recovery? Biopreservation and Biobanking 12: 374–80.
- Barnes, Rebecca O., Brent Schacter, Sugy Kodeeswaran, CTRNet Management Committee, and Peter H. Watson. 2014. Funding sources for Canadian biorepositories: The role of user fees and strategies to help fill the gap. Biopreservation and Biobanking 12: 300–5.
- Baláž, Vladimír, Tomáš Jeck, and Miroslav Balog. 2022. “Economics of Biobanking: Business or Public Good? Literature Review, Structural and Thematic Analysis” Social Sciences 11, no. 7: 288.
- Bourne, L., 2009. Why stakeholders matter. Stakeholder Relationship Management. Farnham: Gower Publishing, pp. 11-27.
- Brown, Tony, Devon D. Kelly, Suzanne M. Vercauteren, William H. Wilson, and Alexander Werner. 2017. How biobanks are assessing and measuring their financial sustainability. Biopreservation and Biobanking 15: 65–71.
- Campos, Antonie H., Marshall Schreeder, Allison Parry-Jones, Ahmed S. Abdelhafiz, Diana Larson, Barbara L. Pruetz, Timothy J. Geddes, Ayat Salman, and Anthola Lazaris. 2015. Addressing the challenge of financial sustainability in biobanking. Biopreservation and Biobanking 13: 387–95.
- Ciaburri, Mirella, Mariorosaria Napolitano, and Elena Bravo. 2017. Business planning in biobanking: How to implement a tool for sustainability. Biopreservation and Biobanking 15: 46–56.
- Evers, Kathinka, Joanna Forsberg, and Mats Hansson. 2012. Commercialization of biobanks. Biopreservation and Biobanking 10: 45–47.
- Gonzalez-Sanchez, Maria B., Ernesto Lopez-Valeiras, and Andreas C. Garcia-Montero. 2014. Implementation of a cost-accounting model in a biobank: Practical implications. Pathobiology 81: 286–97.
- Odeh, Hana, Lisa Miranda, Abhi Rao, Jim Vaught, Howard Greenman, Jeffrey McLean, Daniel Reed, Sarfraz Memon, Benjamin Fombonne, Ping Guan, and et al. 2015. The Biobank Economic Modeling Tool (BEMT): Online Financial Planning to Facilitate Biobank Sustainability. Biopreservation and Biobanking 13: 421–9.
- Parry-Jones, Alison. 2014. Assessing the financial, operational, and social sustainability of a biobank: The Wales Cancer Bank Case Study. Biopreservation and Biobanking 12: 381.
- Uzarski, Diane, James Burke, Barbara Turner, James Vroom, and Nancy Short. 2015. A plan for academic biobank solvency. Leveraging resources and applying business processes to improve sustainability. Cts-Clinical and Translational Science 8: 553–7.
- Watson, P.H., Nussbeck, S.Y., Carter, C., O’donoghue, S., Cheah, S., Matzke, L.A., Barnes, R.O., Bartlett, J., Carpenter, J., Grizzle, W.E., Johnston, R.N., Mes-Masson, A.M., Murphy, L., Sexton, K., Shepherd, L., Simeon-Dubach, D., Zeps, N. and Schacter, B., 2014. A framework for biobank sustainability. Biopreservation and Biobanking 12(1), pp. 60-68.
- Vaught, Jim B. 2013. Economics: The neglected “omics” of biobanking. Biopreservation and Biobanking 11: 259.
About the Author
Bsc. Zoology, BMLS, Msc. Biobanks & Complex data management (In view)
Tijani Abdulrahman is a medical laboratory scientist and a biobanking professional with 10+ years of demonstrated history in working in the medical science practice industry. Skilled in laboratory medicine, biobanking, quality management system and biomedical research. Currently a master’s student at the University Cote d’Azur, France with focus on Biobanking and complex data management. With a multidisciplinary background Tijani Abdulrahman strives to champion biobank and biomedical enabled research in order to strengthen biobank and biomedical innovation.
